Avycaz® (ceftazidime/avibactam) – New indication
February 1, 2018 - Allergan announced the FDA approval of Avycaz (ceftazidime/avibactam), for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible gram-negative microorganisms: Klebsiella pneumonie, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years or older.
Top